📊 XGN Key Takeaways
Is Exagen Inc.. (XGN) a Good Investment?
ExaGen demonstrates revenue growth of 19.7% and healthy 59% gross margins, but faces critical operational sustainability issues. Operating losses of -$3.4M and negative operating cash flow of -$10.4M indicate the business cannot fund itself, while 1.58x debt/equity leverage and negative interest coverage of -6.2x create solvency risk. With -$10.6M annual free cash flow, the company has approximately 2 years of cash runway at current burn rates before facing dilutive capital requirements.
Exagen Inc.. Key Strengths (XGN)
- Revenue growth of 19.7% YoY demonstrates market traction in medical diagnostics sector
- Gross margin of 59% reflects strong underlying unit economics and pricing power
- Current ratio of 3.47x provides adequate short-term liquidity buffer
XGN Stock Risks: Exagen Inc.. Investment Risks
- Operating losses of -$3.4M despite revenue growth indicate inability to achieve cost structure efficiency
- Negative operating cash flow of -$10.4M and free cash flow of -$10.6M demonstrate unsustainable burn rate
- High leverage (1.58x debt/equity) with negative interest coverage (-6.2x) creates imminent solvency risk and dilution probability
Key Metrics to Watch
- Quarterly progress toward operating profitability and positive operating cash flow
- Cash burn rate and remaining runway before forced capital raise
- Gross margin sustainability as company scales and debt service pressure increases
Exagen Inc.. (XGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.47x current ratio provides a solid financial cushion.
XGN Profit Margin, ROE & Profitability Analysis
XGN vs Healthcare Sector: How Exagen Inc.. Compares
How Exagen Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exagen Inc.. Stock Overvalued? XGN Valuation Analysis 2026
Based on fundamental analysis, Exagen Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exagen Inc.. Balance Sheet: XGN Debt, Cash & Liquidity
XGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exagen Inc..'s revenue has grown significantly by 38% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.83 indicates the company is currently unprofitable.
XGN Revenue Growth, EPS Growth & YoY Performance
XGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.5M | -$3.8M | $-0.17 |
| Q3 2025 | $12.5M | -$3.0M | $-0.28 |
| Q2 2025 | $15.1M | -$3.0M | $-0.16 |
| Q1 2025 | $14.4M | -$3.4M | $-0.19 |
| Q3 2024 | $12.5M | -$3.0M | $-0.28 |
| Q2 2024 | $14.1M | -$3.0M | $-0.16 |
| Q1 2024 | $11.2M | -$3.4M | $-0.19 |
| Q3 2023 | $13.4M | -$5.0M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exagen Inc.. Dividends, Buybacks & Capital Allocation
XGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exagen Inc.. (CIK: 0001274737)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XGN
What is the AI rating for XGN?
Exagen Inc.. (XGN) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XGN's key strengths?
Claude: Revenue growth of 19.7% YoY demonstrates market traction in medical diagnostics sector. Gross margin of 59% reflects strong underlying unit economics and pricing power.
What are the risks of investing in XGN?
Claude: Operating losses of -$3.4M despite revenue growth indicate inability to achieve cost structure efficiency. Negative operating cash flow of -$10.4M and free cash flow of -$10.6M demonstrate unsustainable burn rate.
What is XGN's revenue and growth?
Exagen Inc.. reported revenue of $17.3M.
Does XGN pay dividends?
Exagen Inc.. does not currently pay dividends.
Where can I find XGN SEC filings?
Official SEC filings for Exagen Inc.. (CIK: 0001274737) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XGN's EPS?
Exagen Inc.. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is XGN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Exagen Inc.. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is XGN stock overvalued or undervalued?
Valuation metrics for XGN: ROE of -27.5% (sector avg: 15%), net margin of -22.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is XGN's AI grade for 2026?
Our dual AI analysis gives Exagen Inc.. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XGN's free cash flow?
Exagen Inc..'s operating cash flow is $-10.4M, with capital expenditures of $228.0K. FCF margin is -61.5%.
How does XGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -22.9% (avg: 12%), ROE -27.5% (avg: 15%), current ratio 3.47 (avg: 2).
Is Exagen Inc.. carrying too much debt?
XGN has a debt-to-equity ratio of 1.58x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 3.47 suggests adequate short-term liquidity.